Physician profile
Christopher K Manning
NPI 1437124963
$8,663.26
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,217 · 2020: $1,093 · 2021: $1,256 · 2022: $1,996 · 2023: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $101.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $3,340.86 | 2019-2022 | |
| Janssen Biotech, INC. | $564.45 | 2019-2022 | |
| Amgen INC. | $544.26 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $494.87 | 2020-2022 | |
| Abbvie INC. | $401.92 | 2019-2023 | |
| Lilly USA, LLC | $359.76 | 2019-2022 | |
| Pfizer INC. | $349.29 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $329.75 | 2021-2023 | Saphnelo |
| Glaxosmithkline, LLC. | $318.63 | 2019-2022 | |
| Genentech, INC. | $239.75 | 2020 | |
| Mallinckrodt Enterprises LLC | $234.06 | 2019 | |
| Ucb, INC. | $208.50 | 2019-2023 | Cimzia |
| Genentech USA, INC. | $195.82 | 2019-2020 | |
| Sobi, INC | $172.34 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $165.43 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $89.36 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.99 | 2020-2022 | |
| Organon LLC | $66.57 | 2021-2023 | Renflexis |
| Radius Health, INC. | $65.38 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $53.20 | 2021-2022 | |
| Pacira Therapeutics, INC. | $49.33 | 2019-2021 | |
| Almatica Pharma LLC | $48.19 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $47.71 | 2019-2020 | |
| Biogen, INC. | $39.08 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $34.37 | 2019-2020 | |
| Eisai INC. | $31.85 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $24.91 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $23.07 | 2021 | |
| Depuy Synthes Sales INC. | $20.03 | 2020 | |
| Genzyme Corporation | $19.61 | 2020 | |
| Bioventus LLC | $19.08 | 2021 | |
| Medexus Pharma, INC. | $14.68 | 2019 | |
| Assertio Therapeutics, INC. | $14.66 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Manning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.